First Bellwether Trial Begins in the Covidien Hernia Mesh MDL

The first federal bellwether trial in the Covidien Hernia Mesh Products Liability Litigation (MDL No. 3029) is now underway, representing a key milestone. Bellwether trials test central evidence and legal arguments before representative juries. While they do not decide all cases, they offer insight into how future claims may be assessed and can impact settlement negotiations.

The trial is being held in the U.S. District Court for the District of Massachusetts and is the first federal MDL case to reach a jury. Plaintiff Larry Patterson alleges that the Covidien Symbotex hernia mesh was defectively designed and caused serious complications after surgery. The MDL includes over 2,000 pending lawsuits involving Covidien hernia mesh products. Medtronic denies these allegations.

Plaintiffs allege that certain Covidien hernia mesh products caused complications such as chronic pain, adhesions, bowel obstruction, infection, hernia recurrence, mesh failure, and the need for revision or removal surgeries.

During opening statements, Levin Papantonio attorney Timothy O’Brien argued that surgeons were not adequately warned about the duration of the protective collagen barrier’s effectiveness in the Symbotex mesh.

As O’Brien told the jury, “No one will darken that door, come into court, and say we told Larry Patterson’s surgeon it will go away in a week and he implanted it anyway.”

O’Brien argued that Medtronic claimed the collagen barrier would remain effective for approximately 30 days, consistent with an earlier bovine collagen coating. However, he contended that the company knew the newer porcine collagen coating was absorbed within about 7 days, thereby reducing the time the barrier remained in place during the healing process.

“They knew that it did not last anywhere close to the 30 days they were telling surgeons. They were telling surgeons what they wanted to hear.”

Medtronic maintains that the collagen barrier is intended to dissolve as the body heals and forms its own protective tissue. The company also argues that physicians were adequately warned about potential risks through its instructions for use and maintains that its hernia mesh products are safe and effective when used as intended.

About the Litigation and Levin Papantonio’s Role

The federal Covidien Hernia Mesh MDL consolidates lawsuits alleging that certain Covidien hernia mesh products were defectively designed and caused serious injuries following hernia repair surgery. Plaintiffs claim the devices led to complications including chronic pain, infection, adhesions, bowel obstruction, mesh migration, hernia recurrence, and the need for revision or removal surgeries. Medtronic denies those allegations.

Levin Papantonio continues to play a leadership role in the litigation through attorney Timothy O’Brien, who serves on the Plaintiffs’ Executive Committee, a court-appointed leadership group responsible for guiding discovery, coordinating pretrial proceedings, and developing litigation strategy on behalf of plaintiffs nationwide.

O’Brien is a nationally recognized product liability attorney with decades of experience representing clients in complex medical device and pharmaceutical litigation. He has held numerous court-appointed leadership positions in multidistrict litigation.

Sources: Reuters, Law360, Drugwatch.